Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D2C7-IT in Recurrent Malignant Glioma
NCT02303678Phase 1Completed
- Sponsor
- Istari Oncology
- Start
- May 2015
- Primary completion
- May 2019
- Modality
- scFv Fragments, Immunotoxins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of D2C7-(scdsFv)-PE38KDEL in malignant glioma, sponsored by Istari Oncology. Primary endpoint: Maximum Tolerated Dose at 2 weeks. Started May 2015; status: completed.
02
Drugs
D2C7-(scdsFv)-PE38KDEL
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02303678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303678.